Bacterial small-molecule three-hybrid system

• US 7,083,918 B2
• Filed: 04/24/2002
• Issued: 08/01/2006
• Est. Priority Date: 04/24/2002
• Status: Expired due to Fees

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: Althoff, Eric A., Cornish, Virginia W.
• Primary Examiner(s): NAVARRO, ALBERT MARK
• Application Number:
  US10/132,039
• Publication Number:
  US 20030203471A1
• Time in Patent Office: 1,560 Days
• Field of Search: 435/6, 435/7.1, 435/7.2, 435/7.32, 435/7.4
• US Class Current: 435/6.13
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4705 stimulating, promoting or activating activity
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

A transgenic bacterial cell comprising

• • (a) a dimeric small molecule which comprises a first moiety known to bind a first receptor domain covalently linked to a second moiety known to bind a second receptor domain;
  • (b) nucleotide sequences which upon transcription encode
    • i) a first fusion protein comprising the first receptor domain, and
    • ii) a second fusion protein comprising the second receptor domain; and
  • (c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein. The cell is also adapted for use in a method for identifying a molecule that binds to a known target in a bacterial cell from a pool of candidate molecules, and a method for identifying an unknown target receptor to which a molecule is capable of binding in a bacterial cell. Also described are compounds and kits for carrying out the methods.

Claims

1. A method for identifying a molecule that binds a known target receptor in a bacterial cell from a pool of candidate molecules, comprising:

(a) forming a dimeric molecule by covalently bonding each molecule in the pool of candidate molecules to a ligand capable of selectively binding to a receptor;

(b) introducing the dimeric molecule into a bacterial cell culture comprising bacterial cells that express a first fusion protein which comprises the known target receptor domain against which the candidate molecule is screened, a second fusion protein which comprises the receptor domain to which the ligand selectively binds, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;

(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the two fusion proteins into proximity so as to activate the expression of the reporter gene;

(d) selecting the bacterial cell that expresses the reporter gene; and

(e) identifying the small molecule that binds the known target receptor.

6. The method of claim 1, wherein the steps (b)–

(e) of the method are iteratively repeated in the presence of a preparation of random small molecules for competitive binding with the screening molecule so as to identify a molecule capable of competitively binding the known target receptor.

7. The method of claim 1, wherein the dimeric molecule is obtained from a combinatorial library.

8. The method of claim 1, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 100 μ

M.

9. The method of claim 8, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 100 nM.

10. The method of claim 9, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 1 nM.

11. The method of claim 1, wherein the dimeric molecule comprises a methotrexate moiety, FK506 moiety, a tetracycline moiety, or a cephem moiety.

12. The method of claim 1, wherein the dimeric molecule comprises a methotrexate moiety.

13. The method of claim 1, wherein dimeric molecule comprises an FK506 analog having the structure:

14. The method of claim 1, wherein the first fusion protein further comprises a DNA binding domain, and the second fusion protein further comprises a transcription activation domain.

15. The method of claim 1, wherein the first fusion protein further comprises a transcription activation domain, and the second fusion protein further comprises a DNA binding domain.

16. The method of claim 14 or 15, wherein the transcription activation domain is α

NTD.

17. The method of claim 14 or 15, wherein the DNA-binding domain is λ

cI, AraC, LexA, Gal4, or zinc fingers.

18. The method of claim 1, wherein the first or the second fusion protein comprises a receptor domain of dihydrofolate reductase (“

DHFR”

), glucocorticoid receptor, FKBP12, FKBP mutantz, tetracycline repressor, or a penicillin binding protein.

19. The method of claim 18, wherein the DHFR is the E. coli DHFR (“

eDHFR”

).

20. The method of claim 1, wherein the first fusion protein is DHFR-λ

cI or FKBP12-λ

cI.

21. The method of claim 1, wherein the second fusion protein is DHFR-α

NTD or FKBP12-α

NTD.

22. The method of claim 1, wherein the reporter gene is Lac Z, araBAD, aadA, his3, β

-lactamase, GFP, luciferase, TetR, KanR, or Cm.

23. The method of claim 22, wherein the reporter gene is Lac Z.

42. A process for screening a chemical library for a molecule that binds a known target receptor, comprising providing a chemical library, providing a bacterial cell that expresses the known target receptor as a part of a fusion protein, and identifying the molecule that binds the known target receptor in the bacterial cell by the method of claim 1.

2. A method for identifying an unknown target receptor to which a known molecule is capable of binding in a bacterial cell, comprising:

(a) providing a dimeric molecule having a first ligand which has a specificity for the unknown target receptor covalently bonded to a second ligand capable of selectively binding to a receptor;

(b) introducing the dimeric molecule into a bacterial cell which expresses a first fusion protein which comprises the unknown target receptor domain, a second fusion protein which comprises the receptor domain to which the second ligand selectively binds, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;

(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;

(d) selecting which bacterial cell expresses the unknown target receptor; and

(e) identifying the unknown target receptor.

24. The method of claim 2, wherein the unknown target receptor is encoded by a DNA from the group consisting of genomicDNA, cDNA and syntheticDNA.

25. The method of claim 2, wherein the steps (b)–

(e) of the method are iteratively repeated so as to identify the unknown target receptor.

26. The method of claim 2, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 100 μ

M.

27. The method of claim 2, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 100 nM.

28. The method of claim 2, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC₅₀ of less than 1 nM.

29. The method of claim 2, wherein the dimeric molecule comprises a methotrexate moiety, FK506 moiety, a teracycline moiety, or a cephem moiety.

30. The method of claim 2, wherein the dimeric molecule comprises a methotrexate moiety.

31. The method of claim 2, wherein the dimeric molecule is an FK506 analog having the structure:

32. The method of claim 2, wherein the first fusion protein further comprises a DNA binding domain, and the second fusion protein further comprises a transcription activation domain.

33. The method of claim 2, wherein the first fusion protein further comprises a transcription activation domain, and the second fusion protein further comprises a DNA binding domain.

34. The method of claim 32 or 33, wherein the transcription activation domain is α

NTD.

35. The method of claim 32 or 33, wherein the DNA-binding domain is λ

cI, AraC, LexA, Gal4, or zinc fingers.

36. The method of claim 2, wherein the first or the second fusion protein comprises a receptor domain of dihydrofolate reductase (“

DHFR”

), glucocorticoid receptor, FKBP12, tetracycline repressor, or a penicillin binding protein.

37. The method of claim 36, wherein the DHFR is the E. coli DHFR (“

eDHFR”

).

38. The method of claim 2, wherein the first fusion protein is DHFR-λ

cI or FKBP12-λ

cI.

39. The method of claim 2, wherein the second fusion protein is DHFR-α

NTD or FKBP12-α

NTD.

40. The method of claim 2, wherein the reporter gene is Lac Z, araBAD, aadA, his3, β

-lactamase, GFP, luciferase, TetR, KanR, or Cm.

41. The method of claim 40, wherein the reporter gene is Lac Z.

3. A transgenic bacterial cell comprising

(a) a dimeric small molecule which comprises a methotrexate moiety covalently linked to a moiety capable of binding a receptor domain;

(b) nucleotide sequences which upon transcription encode

i) a first fusion protein comprising a DHFR domain and a first fragment of an enzyme, and

ii) a second fusion protein comprising the receptor domain and a second fragment of the enzyme,

wherein activity of the enzyme is conditioned on the proximity of the first fragment of the enzyme to the second fragment of the enzyme.

4. A method for identifying a molecule that binds a known target receptor in a bacterial cell from a pool of candidate molecules, comprising:

(a) forming a dimeric molecule by covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety;

(b) introducing the dimeric molecule into a bacterial cell culture comprising bacterial cells that express a first fusion protein which comprises the known target receptor domain against which the candidate molecule is screened, and a first fragment of an enzyme, and a second fusion protein which comprises a DHFR receptor domain and a second fragment of the enzyme;

(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the first fragment and the second fragment of the enzyme in to proximity so as to reconstitute the activity of the enzyme;

(d) selecting the bacterial cell that exhibits the activity of the enzyme; and

(e) identifying the small molecule that binds the known target receptor.

5. A method for identifying an unknown target receptor to which a known molecule is capable of binding in a bacterial cell, comprising:

(a) providing a dimeric molecule having a first ligand which has a specificity for the unknown target receptor covalently bonded to a methotrexate moiety;

(b) introducing the dimeric molecule into a bacterial cell which expresses a first fusion protein which comprises the unknown target receptor domain, and a first fragment of an enzyme, and a second fusion protein which comprises a DHFR receptor domain and a second fragment of the enzyme;

(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the first fragment and the second fragment of the enzyme in to proximity so as to reconstitute the activity of the enzyme;

(d) selecting the bacterial cell that exhibits the activity of the enzyme; and

(e) identifying the unknown target receptor.